PM 00104

has antineoplastic activity; structure in first source

Also Known As:

N-(((6aS,7R,13S,14S,16R)-5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocin-16-yl)methyl)-3-(3-(trifluoromethyl)phenyl)-2E-propenamide; N-((5-(acetyloxy)-6,6a,7,13,14,16-hexahydro-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocin-16-yl)methyl)-3-(3-(trifluoromethyl)phenyl)-2E-propenamide; PM-00104; PM00104; Zalypsis

Networked: 20 relevant articles (1 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Tetrahydroisoquinolines: 44
        PM 00104: 20

Experts

1.	Avilés, Pablo: 5 articles (01/2017 - 04/2009)
2.	Cuevas, Carmen: 5 articles (04/2014 - 04/2009)
3.	Ocio, Enrique M: 4 articles (01/2017 - 04/2009)
4.	Coronado, Cinthya: 4 articles (02/2016 - 06/2013)
5.	Fernández-Teruel, Carlos: 4 articles (02/2016 - 06/2013)
6.	Alfaro, Vicente: 4 articles (08/2014 - 06/2013)
7.	Siguero, Mariano: 4 articles (08/2014 - 06/2013)
8.	Garayoa, Mercedes: 3 articles (01/2017 - 04/2009)
9.	Gutiérrez, Norma C: 3 articles (01/2017 - 05/2011)
10.	San-Miguel, Jesús F: 3 articles (01/2017 - 04/2009)

Related Diseases

1.	Neoplasms (Cancer) 08/15/2014 - "This manuscript provides a review of current trials and appraises the efficacy of PM00104 as a future cancer treatment. " 02/01/2014 - "A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors." 06/01/2013 - "Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors." 05/01/2013 - "Thirty-seven patients with refractory advanced solid tumors received PM00104 in a toxicity-guided dose escalation study design (3 + 3 patients per cohort). " 06/01/2013 - "Forty-nine patients with advanced solid malignancies received PM00104 following a toxicity-guided, accelerated, dose-escalation design. "
2.	Multiple Myeloma 02/01/2016 - "Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma." 01/01/2017 - "In this context, zalypsis is a novel compound, derived from marine organisms, with a powerful preclinical anti-myeloma effect based on the sensitivity of malignant plasma cells to DNA-damage induction; and it has already been tested in a phase I/II clinical trial in multiple myeloma. " 04/23/2014 - "Zalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. " 01/01/2017 - "Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone."
3.	Ewing Sarcoma (Sarcoma, Ewing) 02/01/2014 - "PM00104 showed modest activity in Ewing sarcoma at 2 mg/m(2) on a weekly schedule. " 02/01/2014 - "An exploratory two-stage, single-arm Phase II multicenter trial of the synthetic alkaloid, PM00104, was conducted in patients with recurrent Ewing sarcoma. " 07/01/2009 - "Finally, PM00104 exerts antiproliferative activity at nanomolar concentrations and induces gamma-H2AX response in two Ewing's sarcoma cell lines, suggesting that gamma-H2AX could serve as a pharmacodynamic biomarker for the clinical development of PM00104." 04/23/2014 - "Zalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. "
4.	Neutropenia 11/01/2012 - "The time course of neutropenia following PM00104 was well characterized by the model developed. " 11/01/2012 - "Simulations indicated that PM00104 dose and dosing interval, but not infusion duration, were the main determinants of the neutropenia severity and duration. " 11/01/2012 - "The objective of this study was to characterize the time course of neutropenia after intravenous PM00104 administration in cancer patients. " 08/01/2014 - "Transient neutropenia (50 % of patients) and thrombocytopenia (33-38 %) were the most common severe hematological abnormalities; their incidence was higher than with single-agent PM00104. " 11/01/2012 - "Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®))."
5.	Endometrial Neoplasms (Endometrial Cancer) 04/23/2014 - "Zalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. "

Related Drugs and Biologics

1.	PM 00104
2.	Trabectedin
3.	Carboplatin (JM8)
4.	PM 01183
5.	Biomarkers (Surrogate Marker)
6.	Proteins (Proteins, Gene)
7.	Doxorubicin (Adriamycin)
8.	Cisplatin (Platino)
9.	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)
10.	Troponin I

Related Therapies and Procedures

1.	Intravenous Infusions
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)